Skip to content
Menu

Truist Securities Reiterates Buy on Biogen, Raises Price Target to $260

Benzinga Newsdesk 3 weeks ago

Analyst RatingsNewsReiterationPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Truist Securities analyst Danielle Brill reiterates Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $235 to $260.

Truist Securities analyst Danielle Brill reiterates Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $235 to $260.

Read at benzinga.com

← All stock news